ARTICLE | Company News

Basilea grants China Resources Holdings rights to Zevtera in China

September 29, 2017 9:40 PM UTC

Basilea Pharmaceutica Ltd. (SIX:BSLN) granted the Shenzhen China Resources Gosun Pharmaceutical Co. Ltd. unit of China Resources Holding Co. Ltd. (Wanchai, China) exclusive rights to develop and commercialize antibiotic Zevtera ceftobiprole in China, including Hong Kong and Macau. Basilea will receive CHF3 million ($3.1 million) up front and is eligible to receive up to CHF145 million ($149.2 million) in regulatory and commercial milestones. Basilea will initially supply Zevtera to CR Gosun at an undisclosed transfer price and will be eligible for tiered double-digit royalties...